SCHEMBL2856240

SCHEMBL2856240

CC(=O)OS(N)(=O)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28535859 0.97
SCHEMBL27839352 0.97
SCHEMBL114520 0.73 ALDH1A1 (0.41)
SCHEMBL28263582 0.71 ALDH1A1 (0.39)
SCHEMBL577100 0.71
SCHEMBL27831111 0.71 ALDH1A1 (0.39)
SCHEMBL27543204 0.71 ALDH1A1 (0.39)
SCHEMBL114521 0.71
SCHEMBL28394309 0.71
SCHEMBL1947040 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112321784-A Bulk polymer and preparation method and application thereof 联泓(江苏)新材料研究院有限公司 2021-02-05 CN claimed
EP-1594884-B1 ANTITUMORAL 18A-HOMOESTRA-1,3,5(10)-TRIEN-3-YL 2-SUBSTITUTED SULFAMATES STERIX LTD (GB) 2010-01-13 EP claimed
US-20090221841-A1 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION STERIX LIMITED (GB) 2009-09-03 US claimed
EP-1594886-B1 ANTITUMORAL D-HOMOESTRA-1, 3, 5 (10)-TRIEN-3-YL 2-SUBSTITUTED SULFAMATES STERIX LTD (GB) 2008-08-27 EP claimed
US-7244762-B2 For therapy of prostate cancer STERIX LIMITED (GB) 2007-07-17 US claimed
US-20060154985-A1 Antitumoral d-homoestra-1,3,5 (10)-trien-3-yl 2-substituted sulfamates STERIX LIMITED (GB) 2006-07-13 US claimed
CN-1751059-A 2-substituted estra-1, 3,5(10) -trien-3-yl sulfamates having antitumor activity SCHERING AG (DE) 2006-03-22 CN claimed
CN-1751060-A Antitumoral 18a-homoestra-1,3,5(10)-trien-3-yl 2-substituted sulfamates SCHERING AG (DE) 2006-03-22 CN claimed
CN-1751061-A Antitumoral d-homoestra-1, 3, 5 (10)-trien-3-yl 2-substituted sulfamates SCHERING AG (DE) 2006-03-22 CN claimed
EP-1517914-B1 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN SCHERING AG (DE) 2005-08-31 EP claimed
CN-1192021-C 3-azabicyclo [3.1.0] hexane derivatives as opioid receptor ligands PFIZER LTD (US) 2005-03-09 CN claimed
US-6583130-B1 Substituted with acyl, oxycarbonyl, aminocarbonyl, sulfonyl, or aminosulfonyl; inhibit steroid sulfatase, do not exhibit any estrogenic effect and will not yield any estrogenic products on hydrolysis; treatment of estrogen-dependent tumors SCHERING AG (DE) 2003-06-24 US claimed
EP-4739669-A1 SODIUM CHANNEL BLOCKERS Novartis AG (CH) 2026-05-13 EP disclosed
WO-2025011450-A1 SODIUM CHANNEL BLOCKERS NOVARTIS AG (CH) 2025-01-16 WO disclosed
CN-118303677-A Aerosol Generating System 尼科创业贸易有限公司 2024-07-09 CN disclosed
CN-113660876-B Aerosol Generating System 尼科创业贸易有限公司 2024-05-28 CN disclosed
CN-1433396-A Pharmaceutical compounds NICOX SA (FR) 2003-07-30 CN disclosed
US-6583130-B1 Substituted with acyl, oxycarbonyl, aminocarbonyl, sulfonyl, or aminosulfonyl; inhibit steroid sulfatase, do not exhibit any estrogenic effect and will not yield any estrogenic products on hydrolysis; treatment of estrogen-dependent tumors SCHERING AG (DE) 2003-06-24 US disclosed
CN-1331679-A 3-azabicyclo [3.1.0] hexane derivatives as opiate receptors ligands PFIZER LTD (US) 2002-01-16 CN disclosed
WO-1992002665-A1 PROCESS FOR CLEANING AND DEGREASING, SPONTANEOUSLY EMULSIFYING PREMIX FOR USE AT THE PROCESS AND THE RESULTING EMULTION ERIKSSON TORD GEORG (SE) 1992-02-20 WO disclosed